🚨 🇺🇸 DANAHER BEATS Q2 ESTIMATES AND RAISES 2026 GUIDANCE AS LIFE-SCIENCE DEMAND GAINS SPEED Danaher posted adjusted EPS of $1.94 versus $1.84 expected, while sales reached $6.27 billion against $6.18 billion forecast. Full-year adjusted EPS guidance rose to $8.45-$8.60. The guidance increase matters more than the quarterly beat. It shows management sees stronger profit momentum across diagnostics, biotechnology and life sciences. $DHR remains the strongest trade. Higher earnings visibility supports the shares, while any slowdown in core revenue growth is the key risk.
View original →